Murugan Subramanian

Dr. Murugan Subramanian

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
LCLotfi Chouchane
Lotfi Chouchane
JGJean-Charles Grivel
Jean-Charles Grivel
EFElmoubasher Abu Baker Abd Farag
Elmoubasher Abu Baker Abd Farag
IPIgor Pavlovski
Igor Pavlovski
SMSelma Maacha
Selma Maacha
JSJingxuan Shan
Jingxuan Shan
The development of prophylactic and therapeutic agents for coronavirus disease 2019 (COVID-19) is a current global health priority. Here, we investigated the presence of cross-neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dromedary camels that were Middle East respiratory syndrome coronavirus (MERS-CoV) seropositive but MERS-CoV free. The tested 229 dromedaries had anti–MERS-CoV camel antibodies with variable cross-reactivity patterns against SARS-CoV-2 proteins, including the S trimer and M, N, and E proteins. Using SARS-CoV-2 competitive immunofluorescence immunoassays and pseudovirus neutralization assays, we found medium-to-high titers of cross-neutralizing antibodies against SARS-CoV-2 in these animals. Through linear B cell epitope mapping using phage immunoprecipitation sequencing and a SARS-CoV-2 peptide/proteome microarray, we identified a large repertoire of Betacoronavirus cross-reactive antibody specificities in these dromedaries and demonstrated that the SARS-CoV-2–specific VHH antibody repertoire is qualitatively diverse. This analysis revealed not only several SARS-CoV-2 epitopes that are highly immunogenic in humans, including a neutralizing epitope, but also epitopes exclusively targeted by camel antibodies. The identified SARS-CoV-2 cross-neutralizing camel antibodies are not proposed as a potential treatment for COVID-19. Rather, their presence in nonimmunized camels supports the development of SARS-CoV-2 hyperimmune camels, which could be a prominent source of therapeutic agents for the prevention and treatment of COVID-19.

30 December 2022 in Sustainability
Verified
Journal Article
Open access
PDF file
AAArfan Ahmed
Arfan Ahmed
SASarah Aziz
Sarah Aziz
UQUvais Qidwai
Uvais Qidwai
FFFaisal Farooq
Faisal Farooq
JSJingxuan Shan
Jingxuan Shan
JSJavaid Sheikh
Javaid Sheikh
Eighty one percent of adolescents aged 11–17 years are inadequately physically active worldwide. Physical activity (PA) recommendations for high school children have not been studied previously in schools in the Qatar region. The objectives of the study were: (i) to assess the level of compliance of the recommended PA and to assess if there are any gender differences; and (ii) to analyze the recommended step count compliance during school and non-school days. An observational cross-sectional study was conducted. Twenty-nine children (12 boys and 17 girls) aged 13–17 years (15.24 ± 1.46) took part in this study. Participants wore Fitbit Charge 5 wrist bands for three weeks to collect various digital biomarkers including moderate-to-vigorous physical activity (MVPA) and step counts (tracking during out-of-school time and school time). Based on this study, high school children in the two Qatar region schools did not meet the MVPA and steps/day recommendation by the established agencies: 38% of the total study group met the recommended 60 min/day of activity (50% boys, 29% girls). Gender differences were also observed in PA levels and steps per day: for non-school days, 17% met the recommended 10,000 steps/day (25% boys, 12% girls). There was a pattern of greater PA performance and steps during the weekdays as opposed to the weekend, but these values showed no robust evidence in favor of H1 or statistical significance for step counts. However, the evidence was robust in favor of H1 (difference between weekend and weekday) due to a statistically significant difference for meeting the 60 min/day activity. While further studies are required to establish if this is a general trend in Qatari schools, this pilot study does highlight the need to design more effective programs and messaging strategies to improve PA levels in the high school population.

1 January 2024 in Advances in Public Health
Verified
Journal Article
Open access
Prasanna Srinivasan RamalingamPrasanna Srinivasan Ramalingam
Prasanna Srinivasan Ramalingam
DRDeepak Balaji Thimiri Govinda Raj
Deepak Balaji Thimiri Govinda Raj
MSMurugan Subramanian
Murugan Subramanian
SASIVAKUMAR ARUMUGAM
SIVAKUMAR ARUMUGAM
Mutant KRAS promotes proliferation and tumorigenesis in several cancers such as colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and non–small cell lung cancer (NSCLC). The long noncoding RNAs (lncRNAs) regulate the microRNAs (miRNAs) that further result in the dysregulation of messenger RNAs (mRNAs) in various mutant KRAS‐associated cancers. Although the role and function of the lncRNA axis are not clearly understood, various studies have recently focussed on the evaluation of the lncRNA axis role in various cancers. The lncRNAs CRNDE and SNHG7 are highly expressed in KRAS‐associated colon adenocarcinoma (COAD), a major subtype of CRC, and further regulate the miRNA expression and thus indirectly regulate mRNA expression levels. In the present study, we have utilized various bioinformatics approaches such as differential gene expression (DEG) analysis, survival analysis, immunohistochemistry (IHC) analysis, prediction of RNA–RNA interaction, miRNA and mRNA stability prediction, and binding energy evaluation. Alongside, machine learning (ML)–based screening was also performed to identify potential miRNA inhibitors from natural source using RDKit. From our study, we have observed that CRNDE sponges hsa‐miR‐181a‐5p and downregulates their expression, and the hsa‐miR‐181a‐5p further regulates the expression of CTNNB1 and TCF4 in COAD. Also, in the lncRNA SNHG7 axis, it regulates the hsa‐miR‐216b‐5p expression, and further, the GALNT1 was downregulated by the binding of hsa‐miR‐216b‐5p. Additionally, ML‐based screening revealed some potential inhibitors particularly based on anthraquinone, quinazoline, and sulfonamide scaffolds against hsa‐miR‐216b‐5p and hsa‐miR‐216b‐5p. Thus, we conclude that the lncRNA/miRNA/mRNA axis of CRNDE/hsa‐miR‐181a‐5p/(CTNNB1/TCF4) and SNHG7/hsa‐miR‐216b‐5p/GALNT1 axes as the significant therapeutic target in the mutant KRAS‐associated CRC, and natural compounds have to be studied more in detail and to be developed as miRNA inhibitors. However, our predictions were supported by the evidence of the interaction and regulation of the lncRNA/miRNA/mRNA axis through bioinformatics approaches and ML‐based miRNA inhibitor screening; it has to be studied further in in vitro and in vivo settings in the near future.

10 November 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
THToshifumi Hara
Toshifumi Hara
MSMurugan Subramanian
Murugan Subramanian
Metastasis is the leading cause of cancer-related mortality, representing a highly coordinated, multistep process in which malignant cells gain the ability to invade, survive in the circulation, and establish secondary tumors at distant sites. While genetic mutations initiate oncogenesis, accumulating evidence shows that epigenetic and epitranscriptomic regulators, encompassing DNA methylation, RNA modifications, and noncoding RNAs (ncRNAs), reshape metastatic phenotypes. This review integrates current insights into these mechanisms and their crosstalk, with a primary focus on their methylation modification. Given their plasticity and potential reversibility, these regulators are attractive targets for therapeutic intervention. Defining the dynamic interplay between DNA and RNA modifications and ncRNAs provides a coherent framework for controlling metastasis and guides the development of precision epigenetic strategies and biomarkers. Future research that integrates multi-omics approaches and spatial transcriptomics will be essential for revealing the epigenetic and epitranscriptomic layers of the metastatic landscape.